All In Biotech

Drug Trial Radar · NCT03682692

ACEI/CCB Versus ACEI/DIU Combination Antihypertensive Therapy in Chinese Hypertensive Patients (ACvAD)

Last checked: Nov 19, 2026Latest source record: Feb 14, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 560 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

560

Actual

Start

Jun 1, 2018

Primary completion

Jun 30, 2021

Study completion Mar 31, 2022

Sponsor

Lead sponsor
Shanghai Jiao Tong University School of MedicineAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 25, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

1. Study name: ACEI/CCB versus ACEI/DIU combination antihypertensive therapy in Chinese hypertensive patients (ACvAD) 2. Rationale:Most current hypertension guidelines recommend the combination therapy of an angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) with a calcium antagonists (CCB) or thiazide diuretics (DIU). However, whether the two combination treatments have similar antihypertensive effects in Chinese hypertensive patients is still lack of clinical evidence, especially randomized controlled trials using ambulatory or home blood pressure measurement as the main evaluation method. 3. Study design: This study is a multi-center, randomized and controlled clinical trial with two equally sized treatment groups: ACEI/CCB group and ACEI/DIU group. 4. Study population: Men or women over 18 years (n=580) meeting the inclusion/exclusion criteria. 5. Randomization and treatment: Potentially eligible patients should receive a 24-hour ambulatory blood pressure monitoring measurement before randomization. After stratification by centers and whether receive antihypertensive treatment, eligible patients will be randomly divided into two groups, taking benazepril 10 mg/amlodipine besylate 5mg fixed-dose combination (1 tablet once a day) or benazepril 10 mg/hydrochlorothiazide 12.5 mg fixed-dose combination (1 tablet once a day). 6. Follow up: All patients should sign an informed consent form before entering the study. The follow-up period is 6 months. 7. Sample size estimation: a total of 580 patients should be enrolled in this study.

Conditions

  • Hypertension

Interventions

  • ACEI/CCBDrug

    benazepril 10 mg / amlodipine besylate 5 mg fixed-dose combination

  • ACEI/DIUDrug

    benazepril 10 mg / hydrochlorothiazide 12.5 mg fixed-dose combination

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 24-hour ambulatory systolic blood pressure reductionTime frame: 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Institite of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.